B60.0 - Plasmodium falciparum malaria
ICD-10 B60.0 is a billable code used to indicate a diagnosis of b60.0 - plasmodium falciparum malaria.
Plasmodium falciparum malaria is a severe form of malaria caused by the protozoan parasite Plasmodium falciparum, which is transmitted to humans through the bite of infected female Anopheles mosquitoes. This disease is prevalent in tropical and subtropical regions, particularly in sub-Saharan Africa. Clinical manifestations can range from mild flu-like symptoms to severe complications such as cerebral malaria, anemia, and multi-organ failure. Diagnosis is typically confirmed through blood smears or rapid diagnostic tests that detect malaria antigens. Treatment involves the use of antimalarial medications, with artemisinin-based combination therapies (ACTs) being the first-line treatment. Prompt diagnosis and treatment are crucial to prevent severe outcomes and reduce mortality rates associated with this disease. Due to the potential for drug resistance, ongoing monitoring and adherence to treatment protocols are essential for effective management.
Detailed patient history, including travel and exposure, laboratory results, and treatment response.
Patients presenting with fever, chills, and travel history to endemic areas.
Consideration of co-morbid conditions and potential complications.
Immediate assessment of symptoms, vital signs, and rapid diagnostic test results.
Patients presenting with acute febrile illness and potential malaria exposure.
Timeliness of diagnosis and initiation of treatment to prevent severe outcomes.
Used for rapid diagnosis of malaria in patients presenting with fever.
Document the reason for the test and results.
Infectious disease specialists may require additional lab results for treatment decisions.
Common symptoms include fever, chills, headache, muscle aches, and fatigue. Severe cases can lead to complications such as cerebral malaria and anemia.
Diagnosis is typically made through blood smears or rapid diagnostic tests that detect malaria antigens.
The first-line treatment is artemisinin-based combination therapy (ACT), which is effective against this severe form of malaria.
